
Chiome Bioscience
Proprietary antibody discovery and development services.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
* | N/A | N/A | IPO |
Total Funding | 000k |


JPY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | 7 % | 48 % | (12 %) | 8 % | 14 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (314 %) | (268 %) | (186 %) | (197 %) | (178 %) | (130 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (314 %) | (269 %) | (208 %) | (197 %) | (179 %) | (131 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 290 % | 241 % | 184 % | 180 % | 154 % | 120 % |
Source: Company filings or news article
Related Content
Chiome Bioscience Inc. is a Japanese biotechnology company established in February 2005 to commercialize the ADLib® system. This proprietary technology, which stands for Autonomously Diversifying Library, was developed in collaboration with the RIKEN research institute and is designed for the rapid discovery of monoclonal antibodies without needing animal immunization. The company went public via an IPO on the Tokyo Stock Exchange on December 20, 2011.
The company's operations are divided into two main segments: the Drug Discovery Business and the Drug Discovery Support Business. The primary focus, shifted in 2017, is the Drug Discovery and Development Business, which involves in-house and collaborative development of therapeutic antibodies for diseases with high unmet medical needs. Its business model centers on licensing out the intellectual property rights of its drug candidates to pharmaceutical companies, generating revenue from upfront payments, milestone fees, and royalties on sales. Key pipeline products include CBA-1205 and CBA-1535, which are in clinical stages.
The Drug Discovery Support Business provides a stable revenue stream by offering technical services to pharmaceutical companies, diagnostic firms, and academic institutions. These services include antibody generation, protein expression and purification, and antibody engineering, utilizing the ADLib® platform. This segment serves major clients like Chugai Pharmaceutical, Ono Pharmaceutical, and Kyowa Kirin. The company also engages in an Integrated Drug Discovery (IDD) model, promoting collaborations to expand its biosimilar business.
Keywords: antibody discovery, ADLib system, drug development, monoclonal antibodies, oncology, biotherapeutics, drug discovery support, licensing, clinical trials, protein engineering, biosimilars, immunotherapy, RIKEN, in-vitro discovery, cell-surface display, antibody generation, therapeutic antibodies, biopharmaceutical, unmet medical needs, cancer treatment